Campos-Murguia A, Roman-Calleja BM, Toledo-Coronado IV, et al. - In patients with COVID-19, a retrospective cohort study was performed to evaluate the presence of metabolic dysfunction-associated fatty liver disease (MAFLD) and fibrosis as well as its link with prognosis. Researchers ascertained the presence of liver steatosis by CT scan in hospitalized patients with COVID-19. They evaluated liver fibrosis using the NAFLD fibrosis score, and when altered, the AST to platelet ratio index score. For this analysis, Mann-Whitney U, Student´s t-test, logistic regression analysis, Kaplan-Meier curves, and Cox regression analysis were applied. A total of 432 patients were included in the study, 40.6% of whom had steatosis. It has been noted that elevated risk for mechanical ventilation, development of AKI, and higher mortality in COVID-19 patients was correlated with the presence of fibrosis rather than the presence of MAFLD. Between patients with and without MAFLD, no differences were found in pulmonary involvement on CT scan, treatment, or number of days between the onset of symptoms and hospital admission.